Population Health Investment Co., Inc.

SPAC Ticker
External link: SEC Filings



Clive Meanwell, Co-Founder; Chief Executive Officer; Director

Clive Meanwell is our co-founder and has been our Chief Executive Officer since September 2020. Dr. Meanwell is a Founding Partner of Population Health Partners. Dr. Meanwell was a founder of The Medicines Company and was a director of The Medicines Company from 1996 until The Medicines Company was acquired by Novartis for $9.7 billion in January 2020. From December 2018 until January 2020, Dr. Meanwell served as The Medicine Company’s chief innovation officer. Prior to December 2018, he served as The Medicine Company’s chief executive officer since February 2012, The Medicine Company’s chief executive officer and president from October 2009 to February 2012, The Medicine Company’s chief executive officer from August 2004 to October 2009, as The Medicine Company’s president from August 2004 to December 2004, The Medicine Company’s executive chairman from September 2001 to August 2004 and The Medicine Company’s chief executive officer and president from 1996 to September 2001. Dr. Meanwell was also chairman of The Medicine Company’s board from September 2001 to August 2015. Dr. Meanwell is the vice chairman of BB Biotech, a Swiss investment corporation. From 1995 to 1996, Dr. Meanwell was a partner and managing director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including senior vice president from 1992 to 1995, vice president from 1991 to 1992 and director of product development from 1986 to 1991. Dr. Meanwell received an M.D. (M.B. Ch.B.) and a Ph.D. (M.D.) from the University of Birmingham, United Kingdom.

Dr. Meanwell’s qualifications to serve on our Board of Directors include his significant experience building and leading successful biotechnology companies, developing pharmaceuticals and his scientific expertise.

Ian Read, co-founder; Executive Chairman; Director

Ian Read is our co-founder and will be our Executive Chairman. Mr. Read has served as the Operating Executive for Global Healthcare at The Carlyle Group since January 2020. Mr. Read was Chairman and Chief Executive Officer of Pfizer from December 2010 until January 2019, and Executive Chairman until December 2019.

Previously, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units—Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Mr. Read is an independent director at Kimberly Clark, having joined that company’s Board of Directors in 2007. He also serves as Chairman of DXC Technology and will become a founding member of the Board of Directors of Viatris upon the completion of that company’s formation.

Mr. Read’s qualifications to serve on our Board of Directors include his significant experience in the global biopharmaceutical industry.

Chris Visioli, Chief Financial Officer

Chris Visioli has been our Chief Financial Officer since September 2020. Mr. Visioli served as Chief Financial Officer and Treasurer of The Medicines Company from March 2018 until January 2020. He previously served as Senior Vice President, Financial Strategy at The Medicine Company from January 2015 to March 2018 and Vice President, Cardiovascular Care from January 2013 to December 2014. Mr. Visioli joined The Medicine Company in June 2003 and worked in a variety of leadership roles in the organization, including finance, business development, investor relations, strategy, planning, and business leadership of the cardiovascular care unit. He led many efforts in the organization to acquire products and establish partnerships in addition to leading long-term strategy and financial planning work. Prior to joining The Medicine Company and before going to business school, Mr. Visioli was a management consultant for Ernst & Young LLP. Mr. Visioli received an M.B.A. with Honors, from Columbia Business School and a B.S. in electrical engineering, cum laude, from Cornell University.

Chris Cox, Senior Vice President

Chris Cox has been our Senior Vice President since September 2020. Mr. Cox is currently a Managing Partner at Population Health Partners. He is also a Senior Counsel at Cadwalader, Wickersham & Taft LLP, which he joined as a partner in January 2012. From February 2016 to March 2019, Mr. Cox was an Executive Vice President and the Chief Corporate Development Officer of The Medicines Company. Prior to January 2012, he was a partner at Cahill Gordon & Reindel. Mr. Cox received a B.S. and a J.D. from the University of Missouri.

Whit Bernard, Senior Vice President

Whit Bernard has been our Senior Vice President since September 2020. Mr. Bernard is currently a Founding Partner at Population Health Partners. From December, 2018 to April, 2020, Mr. Bernard was the Senior Vice President of Commercial Strategy and Business Development for The Medicines Company, which was acquired by Novartis in for $9.7 billion in January 2020.

Prior to joining The Medicines Company, from 2013 to 2018, Mr. Bernard was a consultant in McKinsey’s Pharmaceuticals and Medical Products practice, where Mr. Bernard specialized in portfolio and corporate strategy for early-stage biotechnology companies, as well as commercial strategy for Top 20 pharmaceutical companies. Prior to joining McKinsey, Mr. Bernard worked in the arts, as a Fulbright Scholar in Latvia and then Director of Development at the International Contemporary Ensemble. Mr. Bernard received a B.A. from Brown University and an M.B.A. from the Kellogg School of Management at Northwestern University.

Farah Champsi, Independent Director

Farah Champsi has spent over 30 years evaluating, advising and building companies in the life sciences industry as a Managing Director at Alta Partners, a leading venture capital firm and as a senior banker at Robertson Stephens, a preeminent emerging growth investment bank. From 1987 to 1999, Ms. Champsi was the lead banker for numerous successful initial public offerings, mergers and acquisitions and financings in the biotech industry. In her subsequent role at Alta Partners (2000-present), Ms. Champsi raised over $1 billion in venture funds, served as a board member of 14 public and private companies, and led investments in many companies, including Kite Pharma (acquired by Gilead for $11.9 billion in 2017), Portola Pharmaceuticals (acquired by Alexion Pharmaceuticals for $1.4 billion in 2020), Excaliard Pharmaceuticals (acquired by Pfizer in 2011) and Agensys (acquired by Astellas in 2007).

Ms. Champsi received a B.A. from Smith College and an M.B.A. from Stanford University. She currently serves on the board of UCSF Benioff Children’s Hospitals and as a trustee of Smith College.

We believe the Company will benefit from Ms. Champsi’s extensive network and reputation for constructive, active engagement and trusted working relationships with managements of dynamic, fast-growth companies. Ms. Champsi’s qualifications to serve on our Board of Directors include her significant business and finance experience in the biotech industry.

Clarke Futch, Independent Director

Clarke Futch brings over 30 years of experience in biopharmaceutical/healthcare investing and financing, having raised over $5 billion across eight investment vehicles, and executed more than 100 transactions, including royalty, equity, debt and M&A deals. Since 2001, as co-founder, Managing Partner, and Chairman of the Investment Committee at Healthcare Royalty Partners, he has led or co-led more than 50 royalty and related debt financings representing more than $3 billion of invested capital, involving companies ranging from emerging biopharma to some of the largest global pharmaceutical companies. Before co-founding Healthcare Royalty Partners, Mr. Futch served as a partner at Paul Capital Partners where he co-managed the firm’s royalty investments as a member of the royalty management committee.

Mr. Futch previously served as a founding member of the healthcare group at Thomas Weisel Partners (now Stifel), and as a vice president at Raymond James. He holds a B.A., magna cum laude, from Vanderbilt University and a J.D. from the University of Virginia School of Law.

We believe the company will benefit from Mr. Futch’s expansive network across the biopharmaceutical industry, his decades of experience structuring and executing a broad range of innovative transactions, and his trusted relationships with major institutional investors. Mr. Futch’s qualifications to serve on our Board of Directors include his significant biopharmaceutical investing and financing experience.

Charles Homcy, Independent Director

Charles Homcy, M.D. has served as a director of BridgeBio since November 2018, Chairman of Pharmaceuticals since February 2019, and Lead Director since February 2020. In 2010, Dr. Homcy joined Third Rock Ventures, a venture capital firm, where he is currently a partner. He served as President and Chief Executive Officer of Portola Pharmaceuticals, a clinical biotechnology company, and he served as their President and Chief Executive Officer since co-founding the company in 2003 until 2010. Prior to that, Dr. Homcy served as the President of Research and Development at Millennium Pharmaceuticals, Inc. (currently, Takeda Oncology), a biopharmaceutical company, following its acquisition of COR Therapeutics, Inc. in 2002. He joined COR Therapeutics, Inc., a biopharmaceutical company, in 1995 as Executive Vice President of Research and Development, and he served as a director of the company from 1998 to 2002. Dr. Homcy was a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital from 1997 to 2011.

He was previously president of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth-Ayest Laboratories. He currently serves on the board of directors of Portola Pharmaceuticals, Inc. (Nasdaq: PTLA), a position he has held since 2004, and of Global Blood Therapeutics, Inc. (Nasdaq: GBT). Dr. Homcy received a B.A. and an M.D. from Johns Hopkins University and currently serves on its board of trustees.

We believe the Company will benefit from Dr. Homcy’s experience at biopharmaceutical companies, his significant business leadership and strong medical background. Dr. Homcy’s qualifications to serve on our Board of Directors include his significant biopharmaceutical industry experience.